All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Clinical impact of post-remission therapy after MIDAM regimen in patients with acute myeloid leukemia

By Cynthia Umukoro

Share:

Nov 9, 2018


In a Letter to the Editor of the American Journal of Hematology, Salem Bahashwan and colleagues from Clermont Auvergne University, Clermont-Ferrand, France, reported data from their study which evaluated the efficacy and tolerance of gemtuzumab ozogamicin, intermediate-dose cytarabine, and mitoxantrone (MIDAM) as salvage therapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The impact of post-remission therapy after MIDAM therapy was also evaluated.

Eighty-six patients (median age = 60 years; range: 17–75) with relapsed (n = 62) or refractory (n = 24) AML who were treated with MIDAM regimen between 2008 and 2013 at Clermont Auvergne University Hospital were included in this study. Patients received a MIDAM regimen consisting of gemtuzumab ozogamicin (9 mg/m2 on day 4), cytarabine (1 g/m2 every 12 hours on day 1–5), and mitoxantrone (12 mg/m2/d on day 1–3) as salvage therapy after one (n = 73) or more (n = 13) prior therapy lines. 

Key findings

  • Overall response rate: 63% (54/86)
  • Complete response (CR) rate: 36% (31/86)
  • CR with incomplete platelet count (CRp): 27% (23/86)
  • Eight (9.3%) patients had veno-occlusive disease (VOD) associated with MIDAM regimen
  • Grade 3–4 hyperbilirubinemia and febrile neutropenia occurred in 11 (12.8%) and all patients, respectively
  • Forty-six (53.5%) patients had persistent thrombocytopenia at day 45
  • 30-day mortality rate: 10% (9/86)

Of the 54 patients with CR or CRp, post-remission therapy consisted of chemo-based approaches (chemotherapy only, n = 10; chemotherapy plus autologous transplantation, n = 3) and allogeneic hematopoietic stem cell transplantation (allo-HSCT, n = 29). Seven patients who underwent allo-HSCT received consolidation therapy prior to allo-HSCT.

  • Median follow-up time: 6 years
  • 2-year relapse-free survival (RFS): 28%
    • Allo-HSCT as post-remission therapy led to a significantly better RFS compared to chemo-based and consolidation therapy: 51% vs 33% vs 9%, respectively, P = 0.001
  • 2-year overall survival (OS): 20%
    • Allo-HSCT as post-remission therapy led to a significantly better OS compared to chemo-based approaches: 43% vs 15%, respectively, P = 0.005
  • None of the patients who underwent allo-HSCT had VOD

This study represents the largest cohort of patients treated with MIDAM who have been analyzed. The findings of this study demonstrate that MIDAM regimen is a valid therapeutic option as salvage chemotherapy in patients with R/R AML and it is associated with an “acceptable toxicity profile.”

In addition, allo-HSCT was found to be the consolidation strategy of choice after MIDAM regimen and it is associated with no increased risk of VOD.

References